

**High-Impact Clinical Trials**  
Ballroom C

Moderators: Morgan Grams, MD, PhD, and Philip K.T. Li, MD

- 
- 2:00 p.m. **FR-OR131 Pooled Efficacy and Cardiovascular (CV) Analyses of Roxadustat in the Treatment of Anemia in CKD Patients on and Not on Dialysis** – [Robert Provenzano](#), Steven Fishbane, Lee-Jen Wei, Lynda Szczech, Robert Leong, Khalil G. Saikali, Ming Zhong, Tyson T. Lee, Mark T. Houser, Lars Frison, John Houghton, Thomas B. Neff, Kin-Hung P. Yu
- 2:15 p.m. **FR-OR132 Effect of Angiotensin-Nepriylsin Inhibition on Renal Outcomes in Heart Failure with Preserved Ejection Fraction** – [Finnian R. McCausland](#), Brian Claggett, Nagesh Anavekar, Mauro Gori, Pardeep Jhund, Martin P. Lefkowitz, Martina M. McGrath, John McMurray, Marc A. Pfeffer, Victor Shi, Dirk J. Van veldhuisen, Faiez Zannad, Scott D. Solomon
- 2:30 p.m. **FR-OR133 The Dapagliflozin in Heart Failure with Reduced Ejection Fraction Trial (DAPA-HF): Outcomes in Patients with CKD and Effects on Renal Function** – [Scott D. Solomon](#), Pardeep Jhund, Mikhail Kosiborod, Subodh Verma, Silvio E. Inzucchi, Anna Maria Langkilde, Felipe Martinez, Olof Bengtsson, Kieran F. Docherty, Lars Køber, Mikaela Sjostrand, Marc S. Sabatine, John McMurray
- 2:45 p.m. **FR-OR134 Efficacy and Safety of Difelikefalin in Patients Undergoing Hemodialysis with Pruritus: Results from a Phase 3 Randomized, Controlled Study (KALM-1)** – [Steven Fishbane](#), Aamir Z. Jamal, Warren Wen, Catherine Munera, Frederique Menzaghi
- 3:00 p.m. **FR-OR135 Mycophenolate Mofetil vs. Azathioprine in Kidney Transplant Recipients on Steroid-Free, Low-Dose Cyclosporine Immunosuppression: The ATHENA Trial** – [Paolo Cravedi](#), Piero L. Ruggenti, Francesco Peraro, Annalisa Perna, Giuseppe Remuzzi
- 3:15 p.m. **FR-OR136 A Phase 2 Randomized, Controlled Study of Obinutuzumab with Mycophenolate and Corticosteroids in Proliferative Lupus Nephritis** – [Brad H. Rovin](#), Gustavo Aroca Martinez, Analia Alvarez, Hilda E. Fragoso Ioyo, Adolfinia E. Zuta, Richard Furie, Paul G. Brunetta, Thomas Schindler, Imran Hassan, Matthew Cascino, Jay P. Garg, Ana Malvar
- 3:30 p.m. **FR-OR137 Preventing Early Renal Loss in Diabetes (PERL) Study: Outcome of a 3-Year Trial of Serum Uric Acid Reduction with Allopurinol** – [Alessandro Doria](#), Andrzej Galecki, Cathie Spino, Michael Mauer
- 3:45 p.m. **FR-OR138 Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function and Damage in Type 2 Diabetes** – [Jan H. de Boer](#), Leila R. Zelnick, Andrew N. Hoofnagle, Ravi I. Thadhani, Joann E. Manson
- 4:00 p.m. Adjourn

**Late-Breaking Clinical Trial Posters**  
Exhibit Halls A/B

- TH-PO1183 **Kidney Protection Using the RenalGuard® System in Cardiac Surgery (KIDNEY Study): A Randomised Control Trial Assessing AKI Rate** – [Heyman Luckraz](#), Ramesh Giri, Benjamin J. Wrigley, Kumaresan Nagarajan, Lawrence Beare, Eshan Senanayake, Emma L. Sharman, Alan M. Nevill
- TH-PO1184 **Results of the START-CKD Trial (Strategies Using Darbeopetin Alfa to Avoid Transfusions in CKD)** – [Robert D. Toto](#), Jeffrey Petersen, Jeffrey S. Berns, Eldrin F. Lewis, Qui Tran, Matthew R. Weir
- TH-PO1185 **Phase 3 Study to Compare the Efficacy and Safety of Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, with Darbeopetin Alfa in Anemic Patients with CKD Not Requiring Dialysis** – [Tadao Akizawa](#), Atsushi Matsui, Yuya Miyazawa, Ryosuke Koretomo
- TH-PO1186 **Phase 3 Study to Compare the Efficacy and Safety of Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, with Darbeopetin Alfa in Anemic Patients with CKD Receiving Maintenance Hemodialysis** – [Tadao Akizawa](#), Kazuo Maeda, Yuya Miyazawa, Ryosuke Koretomo
- TH-PO1187 **Efficacy of Tenapanor in Combination with Phosphate Binders in CKD Patients on Dialysis with Uncontrolled Hyperphosphatemia While on Phosphate Binders Alone** – [Pablo E. Pergola](#), Yang Yang, David P. Rosenbaum, Glenn M. Chertow
- TH-PO1188 **Phase 2 Trial of Phytinadione in Calciphylaxis** – [Sagar U. Nigwekar](#)
- TH-PO1189 **Effect of Etelcalcetide in Patients on Hemodialysis with Secondary Hyperparathyroidism: The DUET Trial** – [Yuya Itano](#), Sawako Kato, Hirotake Kasuga, Masato Tsuboi, Makoto Kuro-o, Yachiyo Kuwatsuka, Masahiko Ando, Shoichi Maruyama
- TH-PO1190 **Impact of Phosphate Reduction on Vascular End-Points in CKD (IMPROVE-CKD): A Randomized, Placebo-Controlled Trial** – [Nigel D. Toussaint](#), Eugenia Pedagogos
- TH-PO1191 **A Precision Medicine Approach to Treatment of Osteoporosis in CKD-5D** – [Hartmut H. Malluche](#), Florence Lima, Katelyn M. Hellman, Tara L. Spach, Jin Chen, Daniel Davenport
- TH-PO1192 **A Randomized Crossover Trial of Ultrafiltration (UF)-Profiled Hemodialysis (HD) for UF Rate-Related Harm** – [Jennifer E. Flythe](#), Matthew J. Tugman, Julia Narendra, Magdalene M. Assimon, Quefeng Li, Yueting Wang, Steven M. Brunelli, Alan L. Hinderliter
- TH-PO1193 **Multicenter RCT of Vitamin K Antagonist Replacement by Rivaroxaban with or Without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: The Valkyrie Study** – [An S. De Vriese](#), Rogier Caluwé, Lotte Pyfferoen, Dirk De Bacquer, Koen De Boeck, Joost L. Delanote, Didier P. De Surgeloose, Bruno Van Vlem, Francis Verbeke
- TH-PO1194 **Effects of Exercise Training on Psychosocial Health and Cognition in Elderly Hemodialysis Patients** – [Khin N. Chan](#), Ralph Rabkin, Yu Chen, Atul A. Nagare, Tieming Niu, Yiming Lit, Manjula Kurella Tamura, Jonathan N. Myers
- TH-PO1195 **Safety and Efficacy of the Tablo System: Results from a Prospective, Multi-Center, Cross-Over Study of a First-in-Class Hemodialysis Device in the Home** – [Troy J. Plumb](#), Luis Alvarez, Dennis L. Ross, Joseph J. Lee, Jeffrey Mulhern, Graham E. Abra, Sarah S. Prichard, Glenn M. Chertow, Michael A. Aragon
- TH-PO1196 **A Randomized Cross-Over Trial Using Intradialytic MRI to Compare the Effects of Standard vs. Cooled Haemodialysis on Cerebral Blood Flow and Cardiac Function** – [Venkata R. Gullapudi](#), Eleanor Cox, Charlotte E. Buchanan, Sebastian C. Coleman, Kelly White, Bernard J. Canaud, Maarten W. Taal, Susan Francis, Nicholas M. Selby
- TH-PO1197 **Abstract Withdrawn**
- TH-PO1198 **Effect of Allopurinol on the Progression of CKD: The CKD-FIX Study** – [Sunil Badve](#), Anushree Tiku, Elaine Pascoe, Neil Boudville, Alan Cass, Nicola Dalbeth, Richard O. Day, Janak de Zoysa, Bettina Douglas, Randall Faull, David Harris, Carmel Hawley, Graham R. Jones, John Kanellis, Suetonia Palmer, Vlado Perkovic, Gopi Rangan, Donna Reidlinger, Laura Robison, Robert J. Walker, Giles Walters, David W. Johnson
- TH-PO1199 **A Phase 3 Randomized Controlled Trial on the Effect of Losartan vs. Add-On Aliskiren in CKD** – [Sydney C. Tang](#), Kam wa Chan, Desmond Y. Yap, Gary C. Chan, Kar Neng Lai
- TH-PO1200 **Safety and Efficiency of Nephroprotective Therapy with Ramipril in Children** – [Oliver Gross](#)
- TH-PO1201 **Double-Blind, Randomized Phase 3 Study Comparing Esaxerenone with Placebo in Type 2 Diabetes Patients with Microalbuminuria (ESAX-DN Study)** – [Naoki Kashihara](#), Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori

- TH-PO1202 Canagliflozin (CANA) Slows Declines in Kidney Function in People with Baseline (BL) eGFR <30 mL/min/1.73 m<sup>2</sup> –** George L. Bakris, Megumi Oshima, Kenneth W. Mahaffey, Barry M. Brenner, David M. Charytan, Adeera Levin, Carol A. Pollock, David C. Wheeler, Hong Zhang, Tom Greene, George Capuano, Robert Edwards, Richard Oh, Norm Rosenthal, Meg J. Jardine, Vlado Perkovic
- TH-PO1203 Soluble Tumor Necrosis Factor Receptor 1 (sTNFR1) Is Prognostic for ESRD over 48 Weeks in a Randomized Clinical Trial in Moderate to Advanced Diabetic Kidney Disease (DKD) –** Jacqueline Tarrant, Lene Vestergaard, Emon Elboudwarej, Yuan Tian, Fang Chen, Scott D. Patterson, Uptal D. Patel, Pablo E. Pergola, Glenn M. Chertow, Jan Skupien, Andrzej S. Krolewski
- TH-PO1204 Impact of Canagliflozin (CANA) on eGFR Slope in People with Optimized Glucose Control: Randomized Analyses from CREDENCE –** Meg J. Jardine, Megumi Oshima, Kenneth W. Mahaffey, Rajiv Agarwal, James S. Baldassarre, George L. Bakris, Christopher P. Cannon, George Capuano, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hidjo J. L Heerspink, Adeera Levin, Bruce Neal, Carol A. Pollock, David C. Wheeler, Hong Zhang, Bernard Zinman, Vlado Perkovic
- TH-PO1205 Prevention of CKD with Dapagliflozin: Analysis of the DECLARE-TIMI 58 Trial –** Ofri Mosenzon, Hidjo J. L Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Sabina A. Murphy, Aliza Rozenberg, Ilan Yanuv, Thomas A. Zelniker, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P. Wilding, Ingrid A. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Marc S. Sabatine, Stephen Wiviott, Itamar Raz
- TH-PO1206 Randomized Controlled Trial of Tacrolimus vs. Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease –** Megan Griffith, Nicholas R. Medjeral-Thomas
- TH-PO1207 A Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients with Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID) –** Ladan Zand, Nelson Leung, Sanjeev Sethi, S. Vincent Rajkumar, Fernando C. Fervenza
- TH-PO1208 Intensive Supportive Care Plus Immunosuppression in IgA Nephropathy: Long-Term Renal Outcomes –** Jürgen Floege, Stephanie Wied, Christina Fitzner, Frank Eitner, Claudia Sommerer, Martin G. Zeier, Britta Otte, Ulf Panzer, Klemens Budde, Urs Benck, Peter R. Mertens, Uwe Kuhlmann, Oliver Witzke, Oliver Gross, Volker Vielhauer, Johannes F. Mann, Ralf-dieter Hilgers, Thomas Rauen
- TH-PO1209 The Gut-Kidney Axis in Man: GLP-1's Natriuretic Action Is Abolished by the GLP-1 Receptor Antagonist Exendin 9-39 –** Ali Asmar, Per K. Cramon, Meena Asmar, Lene Simonsen, Charlotte M. Sorensen, Sten Madsbad, Peter Hovind, Jens J. Holst, Boye Jensen, Jens Bülow
- TH-PO1210 Concordance Between AKI and Blood Pressure (BP) Assessment in Routine Clinical Practice and Research: Results from the SPRINT Electronic Health Record (EHR) Ancillary Study –** Paul E. Drawz, Mahboob Rahman, Delphine S. Tuot, Michael V. Rocco, Nicholas M. Pajewski
- TH-PO1211 Lack of Concordance Between Changes in the Serum Creatinine and Measured GFR in Patients with Acute Decompensated Heart Failure –** Jutta S. Swolinsky, Enkhtuvshin Tuvshinbat, Fabian Knebel, Edis Gasanin, Daniel Meier, Kai-Uwe Eckardt, Bruce A. Molitoris, Kai M. Schmidt-Ott
- TH-PO1212 Water Intake and Blood Pressure in Children: Results from the SPA Project –** Gianluigi Ardissino, Michela Perrone, Silvia A. Ghiglia, Patrizia Salice, Francesca Tel, Valentina Capone, Sandra Piantanida, Silvia Di michele
- TH-PO1213 ANG-3777 Improves Outcomes in Patients with Delayed Graft Function: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial with 12-Month Follow-Up –** Jonathan Bromberg, Matthew R. Weir, Ahmed O. Gaber, Barry Browne, Itzhak D. Goldberg, Michael A. Yamin, Tracy J. Mayne, Matthew Cooper
- TH-PO1214 Durable Donor Hematopoietic Stem Cell (HSC) Chimerism Is Associated with Protection from Native Renal Autoimmune Disease Recurrence in Recipients of Combined Stem Cell/Kidney Transplants –** Joseph R. Leventhal, John P. Galvin, Lorenzo G. Gallon, Dianne S. Belshe, David Tollerud, Suzanne T. Ildstad

*Posters will be on display during exhibit hall hours (9:30 a.m. – 2:30 p.m.).*